Oral alkaline phosphatase - Theriva Biologics
Alternative Names: Oral intestinal alkaline phosphatase - Theriva Biologics; SYN-020Latest Information Update: 03 Apr 2023
At a glance
- Originator Synthetic Biologics
- Developer Theriva Biologics
- Class Anti-inflammatories; Anti-ischaemics; Hepatoprotectants; Phosphoric monoester hydrolases; Recombinant proteins
- Mechanism of Action Alkaline phosphatase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Coeliac disease; Inflammatory bowel diseases; Metabolic syndrome; Non-alcoholic fatty liver disease; Radiation injuries
Most Recent Events
- 30 Mar 2023 Oral alkaline phosphatase - Theriva Biologics is available for licensing as of 30 Mar 2023. https://therivabio.com/
- 12 Oct 2022 Synthetic Biologics is now called Theriva Biologics
- 10 May 2022 Interim adverse events and pharmacokinetics data from a phase I multiple ascending dose (MAD) trial in Healthy volunteers released by Synthetic Biologics